Answers are grounded in this paper and cite their sources.
Phase II trial finds dynamic changes in regulatory CD4+ T cells after durvalumab and tremelimumab treatment, indicating its potential in head and neck cancer.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: